Articles

Pharma Gets Social: Pinterest for Pharma, revisited

17th April 2014

Pharma Gets Social: Pinterest for Pharma, revisitedDaniel Ghinn

Daniel Ghinn provides an update on pharma's use of Pinterest since he last wrote about it two years ago. He updates us on the pharma companies who have adopted this... Read more

Tunnah’s musings: Social media in the pharma boardroom

16th April 2014

Tunnah’s musings: Social media in the pharma boardroomPaul Tunnah

Attending the Boehringer Ingelheim annual press conference, Paul Tunnah took the opportunity to catch up with its head of sales and marketing, Allan Hillgrove, to understand what is behind the... Read more

When measuring European regulatory approval, the timestamp matters

16th April 2014

When measuring European regulatory approval, the timestamp mattersDaniel Sanchez, MA and Yin Ho, MD, MBA

Daniel Sanchez and Yin Ho explore the concept of cycle time in regulatory decisions in the pharma industry and their significance in market access. They consider the FDA compared with... Read more

The impact of Western diseases on Latin America

15th April 2014

The impact of Western diseases on Latin AmericaLuke Sewell

Luke Sewell highlights the burden of Western diseases such as cancer, diabetes and obesity on Latin America in pharmaphorum's emerging markets themed month.How Western diseases are impacting Latin AmericaThe disease... Read more

News

NHS England approves early funding for Sovaldi

17th April 2014

NHS England is to spend £18.7 million to make new Hepatitis C treatment Sovaldi available to patients with the most advanced disease.Around 500 patients who have acute liver failure, and/or... Read more

US approval for Glaxo’s Tanzeum

16th April 2014

US approval for Glaxo’s TanzeumAndrew McConaghie

GlaxoSmithKline has gained FDA approval for its new diabetes treatment Tanzeum.The drug is the latest contender in the GLP-1 class of diabetes treatments, and is taken once a week for... Read more

Boehringer pursues aggressive new products strategy

16th April 2014

Boehringer pursues aggressive new products strategyPaul Tunnah

Boehringer Ingelheim announces flat growth for 2013 and anticipates a tough 2014, but pins future growth on aggressive R&D investment delivering more than 10 new product launches by 2016, to... Read more

Sovaldi ‘cost effective but not affordable’ for NHS

15th April 2014

Sovaldi ‘cost effective but not affordable’ for NHSAndrew McConaghie

A leading charity says new Hepatitis C drug Sovaldi is a huge step forward in treating the disease – but says its high price means it is not affordable for... Read more

Audio & Video

Rare Disease Day tweetchat

 

To view a full transcript of the discussion from this #hcsmeu tweetchat held on 28th February 2014 please click View more

Is there common ground for engagement be…

Doctors net webinar

 

The growth of online networks for doctors has been accompanied by recognition from the pharmaceutical industry that these digital meeting grounds can be... View more

Executive Perspectives: Jane Griffiths

 

In the latest in our series of interviews with senior executives who are steering the global pharma industry through a period of unparalleled change, pharmaphorum... View more

Full round table: Oncology shaping the …

 

Watch the full round table video debate on 'oncology shaping the... View more

White Papers

Who are the pharma social media butterfl…

Who are the pharma social media butterflies?Joanne Wunder, Caroline Howe, Andrea Visone and Laura Clewes

Social media has got everyone talking and it seems like everyone in pharma is talking about social media, so Ogilvy Healthworld figured it was time to analyse who were the... View info

Engage with confidence: Managing online …

Engage with confidence: Managing online adverse event reportingSiva Nadarajah

The pharmaceutical industry is waking up to the enormous potential offered by social media and other online data sources for informing better decisions around drug development and commercialization. Here, Siva... View info

Digital excellence in the global pharmac…

Digital excellence in the global pharmaceutical industry in 2014Tim van Tongeren and Dennis van Rooij

As pharmaceutical companies all look to step up their digital capabilities, this survey of digital leaders from across big pharma, exclusively first published on pharmaphorum, reveals an interesting picture of... View info

Patient research – the changing landscap…

Patient research – the changing landscape: Harnessing the voice of the citizen expertBrian Mondry and Jo Boxall

Empowered patients, or citizen experts as they are often called, are becoming one of the most powerful forces in healthcare, which means the pharmaceutical industry must learn to effectively engage... View info

Further News & Articles

Will pharma forsake emerging markets?

In pharmaphorum's emerging markets themes month, Salil Kallianpur questions the importance of the emerging markets t... Read more

Articles

Don’t underestimate the potential of new products

John Ansell shows how much better the products launched a decade ago have performed than expected at the time, an... Read more

Articles

Winds of change for pricing and funding in Spain (Part II)

In the concluding part of this two-part article exploring the drug pricing environment in Spain, Beatriz Casado and ... Read more

Articles

Winds of change for pricing and funding in Spain (Part I)

In part one of this two-part article exploring the drug pricing environment in Spain, Beatriz Casado and Kathrine Ka... Read more

Articles

AbbVie’s Hepatitis C drug works in difficult to treat patients

New data on AbbVie's three-pronged Hepatitis C treatment shows the combination helped patients whose infectio... Read more

News

Thailand pharmaceutical market update 2014

This article looks at the pharmaceutical market in Thailand in pharmaphorum's emerging market themed month.
Read more

Articles